Author:
Walitza Susanne,Banaschewski Tobias,Häge Alexander
Publisher
Springer Berlin Heidelberg
Reference38 articles.
1. AWMF (2018) S3-Leitlinie „Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Kindes-, Jugend- und Erwachsenenalter“. AWMF-Register Nr. 028–045. https://www.awmf.org/leitlinien/detail/ll/028-045.html. Zugegriffen: 30. Okt. 2021
2. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A (2004) Non-stimulant medications in the treatment of ADHD. Eur Child Adoles Psychiatry 13:i102–i116
3. Bangs ME, Tauscher-Wisniewski S, Polzer J et al. (2008) Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 47:209–218
4. CADDRA (Canadian Attention Deficit Hyperactivity Disorder Resource Alliance) (2020) Canadian ADHD practice guidelines, 4, 1. Aufl. CADDRA, Toronto
5. Chang Z, Lichtenstein P, Halldner L et al. (2014) Stimulant ADHD medication and risk for substance abuse. J Child Psych Psychiatry 55:878–885